OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Incidence, timing, and management of infections in patients receiving teclistamab for the treatment of relapsed/refractory multiple myeloma in the MajesTEC‐1 study
Ajay K. Nooka, Cesar Rodriguez, María‐Victoria Mateos, et al.
Cancer (2023) Vol. 130, Iss. 6, pp. 886-900
Open Access | Times Cited: 32

Showing 1-25 of 32 citing articles:

Teclistamab impairs humoral immunity in patients with heavily pretreated myeloma: importance of immunoglobulin supplementation
Kristine A. Frerichs, Christie P.M. Verkleij, María‐Victoria Mateos, et al.
Blood Advances (2023) Vol. 8, Iss. 1, pp. 194-206
Open Access | Times Cited: 33

Efficacy and safety of teclistamab in patients with relapsed/refractory multiple myeloma after BCMA-targeting therapies
Cyrille Touzeau, Amrita Krishnan, Philippe Moreau, et al.
Blood (2024) Vol. 144, Iss. 23, pp. 2375-2388
Open Access | Times Cited: 12

Real-world evaluation of teclistamab for the treatment of relapsed/refractory multiple myeloma (RRMM): an International Myeloma Working Group Study
Carlyn Tan, Sireesha Asoori, Chiung‐Yu Huang, et al.
Blood Cancer Journal (2025) Vol. 15, Iss. 1
Open Access | Times Cited: 1

Charting the Course: Sequencing Immunotherapy for Multiple Myeloma
Meera Mohan, Oliver Van Oekelen, Othman Salim Akhtar, et al.
American Society of Clinical Oncology Educational Book (2024) Vol. 44, Iss. 3
Closed Access | Times Cited: 7

Bispecific Antibody Use in Patients With Lymphoma and Multiple Myeloma
Adam Braun, Sushanth Gouni, Astrid E. Pulles, et al.
American Society of Clinical Oncology Educational Book (2024) Vol. 44, Iss. 3
Closed Access | Times Cited: 6

Sustained remission following finite duration bispecific antibody therapy in patients with relapsed/refractory myeloma
Rajshekhar Chakraborty, Heloise Cheruvalath, Anannya Patwari, et al.
Blood Cancer Journal (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 5

Proposal for harmonizing the reporting of infections during treatment with bispecific antibodies in multiple myeloma
Heinz Ludwig, Nikhil Munshi, Evangelos Terpos, et al.
Blood Advances (2024) Vol. 8, Iss. 18, pp. 4979-4982
Open Access | Times Cited: 4

Novel Treatment Options for Multiple Myeloma
Andrew J. Portuguese, Rahul Banerjee, Gui Zhen Chen, et al.
JCO Oncology Practice (2025)
Closed Access

Balancing the Scales: Optimizing Reporting of Infection Rates in Clinical Trials of Bispecific Antibodies in Multiple Myeloma
Joshua Richter, Madhav V. Dhodapkar, Mengying Li, et al.
American Journal of Hematology (2025)
Closed Access

Perspectives on Outpatient Delivery of Bispecific T-Cell Engager Therapies for Multiple Myeloma
Andrée-Anne Pelland, Marc‐Emmanuel Dumas, Émilie Lemieux‐Blanchard, et al.
Current Oncology (2025) Vol. 32, Iss. 4, pp. 238-238
Open Access

T-Cell Redirecting Therapies in Multiple Myeloma: Pathogenesis and Management of Toxicities Beyond CRS and ICANS
Katia Mancuso, Marco Talarico, Enrica Manzato, et al.
Cancers (2025) Vol. 17, Iss. 9, pp. 1514-1514
Open Access

Herpesvirus Infections After Chimeric Antigen Receptor T-Cell Therapy and Bispecific Antibodies: A Review
Joseph Sassine, Emily A Siegrist, Roy F. Chemaly
Viruses (2025) Vol. 17, Iss. 1, pp. 133-133
Open Access

Minimal residual disease negative: A novel endpoint for accelerated approval; What providers should know
Sruthi Ranganathan, Vinay Prasad
Journal of Cancer Policy (2025), pp. 100588-100588
Closed Access

Improving outcomes with anti-BCMA bispecific antibodies with attention to infection
Andrew J. Yee
Blood Cancer Journal (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 3

How to manage prolonged immune effector cell-associated hematotoxicity (ICAHT) related to BCMA-directed myeloma therapy
James A. Davis, Mary McGann, Jessica Marini, et al.
Expert Review of Anticancer Therapy (2024) Vol. 24, Iss. 6, pp. 335-338
Open Access | Times Cited: 2

Risk of infection in patients with multiple myeloma treated with T-cell redirecting approaches: a call out for clinicians
Tommaso Lupia, Lorenzo Cani, Sara Bringhen, et al.
Clinical Lymphoma Myeloma & Leukemia (2024) Vol. 24, Iss. 9, pp. 592-603
Closed Access | Times Cited: 2

Progressive Multifocal Leukoencephalopathy Unmasked by Teclistamab in a Refractory Multiple Myeloma Patient
Panos Arvanitis, Dimitrios Farmakiotis, Ari Pelcovits
Current Oncology (2024) Vol. 31, Iss. 5, pp. 2670-2678
Open Access | Times Cited: 2

Multiple Myeloma: A Personal Account of My Journey With the Disease and Response to Teclistamab
Mohammad Ahmad, Musa F Zahrani, Ghazi Alotaibi, et al.
Cureus (2024)
Open Access | Times Cited: 1

Defining infection risk of bispecific antibodies for myeloma
Sarah P. Hammond
Blood Advances (2024) Vol. 8, Iss. 18, pp. 4977-4978
Open Access | Times Cited: 1

Impact of COVID-19 on outcomes with teclistamab in patients with relapsed/refractory multiple myeloma in the phase 1/2 MajesTEC-1 study
Niels W.C.J. van de Donk, Nizar J. Bahlis, Luciano J. Costa, et al.
Blood Cancer Journal (2024) Vol. 14, Iss. 1
Open Access | Times Cited: 1

Comprehensive review of bispecific antibody constructs in multiple myeloma: affinities, dosing strategies and future perspectives
Johannes M. Waldschmidt, Leo Rasche, K. Martin Kortüm, et al.
Clinical Lymphoma Myeloma & Leukemia (2024)
Closed Access | Times Cited: 1

Page 1 - Next Page

Scroll to top